Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding (SRRK)
:SRRK
SRRK Stock Chart & Stats
$37.41
-$0.51(-1.26%)
At close: 4:00 PM EST
$37.41
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$22.71 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)2.84M
Market Cap
$3.60B
Enterprise ValueN/A
Total Cash (Recent Filing)$369.63M
Total Debt (Recent Filing)$110.08M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 10, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding96,127,266
10 Day Avg. Volume2,072,936
30 Day Avg. Volume2,835,972
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.71
Price to Sales (P/S)0.00
P/FCF Ratio-21.46
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$47.22Price Target Upside26.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyApitegromab is the first myostatin-targeting therapy to show a statistically significant benefit in motor function in a pivotal trial.
Market OpportunityThere is a significant market opportunity for apitegromab in SMA, with risk-adjusted peak sales modeled at $2bn in 2037.
Regulatory ProgressScholar Rock has contracted an additional US fill finish facility with a strong regulatory track record to accelerate timelines for a potential US launch.
Bears Say
Market VolatilityScholar Rock's shares are expected to remain volatile and very sensitive to any additional headlines or disclosures in the near term.
Operational ChallengesA warning letter is likely following the OAI, which could delay corrective actions.
Regulatory DelaysThe Catalent Indiana facility, acquired by Novo Nordisk, received an Official Action Indicated (OAI) classification, which is seen as a net negative for near-term approval prospects for Scholar Rock's apitegromab.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $22.71 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $3.60B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Mar 10, 2026 which is in 114 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on Nov 14, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.842 by -$0.058.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.86.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 96,127,266 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.842. Following the earnings report the stock price went up 24.41%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.22 (26.22% Upside)
$47.22 (26.22% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 197.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $18.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 17.9%
Last 30 Days ▲ 17.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.03%
12-Months-Change
Fundamentals
Return on Equity
-218.04%
Trailing 12-Months
Asset Growth
129.84%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of optimism due to strong financial management, significant trial results for apitegromab, and strategic preparation for commercial launch. However, these positives are tempered by regulatory delays and uncertainties surrounding the approval timeline due to third-party facility compliance issues.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$47.22
▲(26.22% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
23.39% Insiders
32.45% Mutual Funds
0.08% Other Institutional Investors
32.83% Public Companies and Individual Investors